Uncommon_Mutations_Database

New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib  New searchable database of published clinical outcomes from patients with uncommon EGFR mutations in advanced/metastatic NSCLC treated with afatinib, reported by individual mutation, is available for global clinician use at:www.uncommonEGFRmutations.comPooled analysis of 693 NSCLC patient cases published in the Journal of Thoracic Oncology (JTO) supports the use of afatinib against the most prevalent uncommon EGFR mutations
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news